Evidence map›Paper›PMID 38803186›Full record

ArticleCurrent drug metabolism2024

Avapritinib Carries the Risk of Drug Interaction

Xin Lv, Zhen Wang, Zhe Wang, Hang Yin, Yangliu Xia, Lili Jiang, Yong Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Current drug metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xin LvSchool of Chemical Engineering, Ocean and Life Sciences, Dalian University of Technology, Panjin, 124221, China.
Zhen WangSchool of Chemical Engineering, Ocean and Life Sciences, Dalian University of Technology, Panjin, 124221, China.
Zhe WangSchool of Chemical Engineering, Ocean and Life Sciences, Dalian University of Technology, Panjin, 124221, China.
Hang YinSchool of Chemical Engineering, Ocean and Life Sciences, Dalian University of Technology, Panjin, 124221, China.
Yangliu XiaSchool of Chemical Engineering, Ocean and Life Sciences, Dalian University of Technology, Panjin, 124221, China.
Lili JiangSchool of Chemical Engineering, Ocean and Life Sciences, Dalian University of Technology, Panjin, 124221, China.
Yong LiuSchool of Chemical Engineering, Ocean and Life Sciences, Dalian University of Technology, Panjin, 124221, China.

Funding

Fundamental Research Funds for the Central Universities DUT21LK11,DUT21LK11National Natural Science Foundation of China 82274006
6 · The paper itself

Abstract

backgroundAvapritinib is the only drug for adult patients with PDGFRA exon 18 mutated unresectable or metastatic gastrointestinal stromal tumor (GIST). Although avapritinib has been approved by the FDA for four years, little is known about the risk of drug-drug interactions (DDIs) via UDP-glucuronyltransferases (UGTs) inhibition.

objectiveThe aim of the present study was to systematically evaluate the inhibitory effects of avapritinib against UGTs and to quantitatively estimate its potential DDIs risk

methodsRecombinant human UGTs were employed to catalyze the glucuronidation of substrates in a range of concentrations of avapritinib. The kinetics analysis was performed to evaluate the inhibition types of avapritinib against UGTs. The quantitative prediction of DDIs was done using

resultsAvapritinib had a potent competitive inhibitory effect on UGT1A1. Quantitative prediction results showed that avapritinib administered at clinical doses might result in a 14.85% increase in area under the curve (AUC) of drugs primarily cleared by UGT1A1. Moreover, the Rgut value was calculated to be 18.44.

conclusionAvapritinib has the potential to cause intestinal DDIs

Indexed as

Drug InteractionsGlucuronosyltransferaseAntineoplastic AgentsAvapritinibHumansPyrazolesPyrrolesTriazinesUGT1A1 EnzymeAntineoplastic AgentsAvapritinibGlucuronosyltransferasePyrazolesPyrrolesTriazinesUGT1A1 EnzymeAvapritinibdrug-drug interactionmetastatic GIST.stromal tumorUDP-glucuronosyltransferaseUGT1A1

Identifiers

PMID38803186

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.